CATALYSTSeekingAlpha • 1d ago
Viking Therapeutics: A Strong Injection, A Scaled-Back PillViking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, with Phase 3 injection results expected in 2027. Read why VKTX stock is a hold.
Why VKTX Stock surged +5.92% Today — RQD Quant Desk Flash
$26.86 +5.92% NASDAQ • Public Delayed / 60s Snapshot
Viking Therapeutics Inc. (VKTX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $3.38B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($2.7M)
40% PutsMax Pain: $26.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VKTX Stock surged +5.92% Today — RQD Quant Desk Flash
Viking Therapeutics Inc. (VKTX) surged +5.92% to $26.86 as options desks priced 60% call premium vs. 40% put protection around the $26 max-pain magnet. Solid 44% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 16% of its 52-week range ($23.82 – $43.15) with RSI-14 at 48 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.7M in bullish call flow vs. $1.8M in put flow (Put/Call 0.68x, implied earnings swing ±6.6%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 0% gross margin and $0 annual free cash flow.
Live VKTX Headlines & Catalysts
CATALYSTBenzinga • 1d ago
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $118.
MARKET WIREYahoo • 1d ago
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
MARKET WIREYahoo • 1d ago
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetBased on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly s
MARKET WIRESeekingAlpha • 2d ago
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market. I rate VKTX stock as Hold. Read my full update now.
RISK WATCHYahoo • 2d ago
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
CATALYSTYahoo • 2d ago
LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedLilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
CATALYSTYahoo • 2d ago
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesEli Lilly (NYSE:LLY) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely movin
RISK WATCHYahoo • 2d ago
VKTX Q3 Earnings Call Highlights Obesity Pipeline ProgressViking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.
MARKET WIREYahoo • 2d ago
Viking Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby summary of Viking Therapeutics, Inc.'s Q3 2026 earnings call
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live VKTX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
VKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.51%📐 HORIZONTAL RANGE
2026-10-30O $26.77H $27.83L $26.31C $27.28VOL 5.14M
RES: $43.25SUP: $23.32SMA50: $30.51SMA200: $32.40
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
27.0%/yr Implied 5Y Growth
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VKTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VKTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
VKTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VKTX stock moving today?
Why VKTX Stock surged +5.92% Today — RQD Quant Desk Flash. Solid 44% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.